source
- Zealand Pharma to invest up to $1.2 billion in Generate’s AI platform for obesity drug developmentZealand Pharma announced a partnership with Generate:Biomedicines to use the latter's generative‑AI platform for creating new multispecific drug candidates aimed at obesity and metabolic disorders.…
- Verastem reports promising early results for KRAS G12D inhibitor in pancreatic and lung cancersVerastem Oncology has shifted its research toward a KRAS G12D inhibitor, VS-7375, and released early data from a phase 1/2 study involving more than 200 patients with advanced KRAS G12D-mutated sol…